title: Mammaglobin-A is a target for breast cancer vaccination.
abstract: We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadjuvant endocrine therapy, providing a unique opportunity to examine the impact of vaccination in the tumor microenvironment.
authors.affiliation: Department of Surgery, Washington University School of Medicine , St. Louis, MO, USA.
authors.forename: Samuel W
authors.initials: SW
authors.lastname: Kim
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA; The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Goedegebuure
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA; The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: William E
authors.initials: WE
authors.lastname: Gillanders
keywords: Cancer vaccine; DNA vaccine; T cells; breast cancer; immunotherapy; mammaglobin-A